» Articles » PMID: 26130187

Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD)

Overview
Journal Drugs
Specialty Pharmacology
Date 2015 Jul 2
PMID 26130187
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Meibomian gland (MG) dysfunction (MGD) is a multifactorial, chronic condition of the eyelids, leading to eye irritation, inflammation and ocular surface disease. Initial conservative therapy often includes a combination of warm compresses in addition to baby shampoo or eyelid wipes. The practice of lid hygiene dates back to the 1950s, when selenium sulfide-based shampoo was first used to treat seborrhoeic dermatitis of the eyelids. Today, tear-free baby shampoo has replaced dandruff shampoo for MGD treatment and offers symptom relief in selected patients. However, many will not achieve significant improvement on this therapy alone; some may even develop an allergy to the added dyes and fragrances in these products. Other manual and mechanical techniques to treat MGD include MG expression and massage, MG probing and LipiFlow(®). While potentially effective in patients with moderate MGD, these procedures are more invasive and may be cost prohibitive. Pharmacological treatments are another course of action. Supplements rich in omega-3 fatty acids have been shown to improve both MGD and dry eye symptoms. Tea tree oil, specifically the terpenin-4-ol component, is especially effective in treating MGD associated with Demodex mites. Topical antibiotics, such as azithromycin, or systemic antibiotics, such as doxycycline or azithromycin, can improve MGD symptoms both by altering the ocular flora and through anti-inflammatory mechanisms. Addressing and treating concurrent ocular allergy is integral to symptom management. Topical N-acetylcysteine and topical cyclosporine can both be effective therapeutic adjuncts in patients with concurrent dry eye. A short course of topical steroid may be used in some severe cases, with monitoring for steroid-induced glaucoma and cataracts. While the standard method to treat MGD is simply warm compresses and baby shampoo, a more tailored approach to address the multiple aetiologies of the disease is suggested.

Citing Articles

How Eyelid Changes May Impact on Tears.

Di Zazzo A, Villani E, Barabino S, Giannaccare G J Clin Med. 2024; 13(22).

PMID: 39598071 PMC: 11594652. DOI: 10.3390/jcm13226927.


Therapeutic effectiveness of different machines in intense pulsed light treatment of meibomian gland dysfunction.

Qin Z, Zhu Y, Lu J, Lin L, Huo Y, Wang H Adv Ophthalmol Pract Res. 2024; 4(4):182-188.

PMID: 39295913 PMC: 11407992. DOI: 10.1016/j.aopr.2024.06.002.


Effects of combined intense pulsed light and cyclosporine 0.05% eyedrops in ocular surface matrix metalloproteinase-9 levels in patients with moderate-to-severe MGD.

Jeon Y, Bae S, Chung H, Kim J, Lee H Lasers Med Sci. 2024; 39(1):203.

PMID: 39088100 DOI: 10.1007/s10103-024-04154-4.


Comparison of a single-dose vectored thermal pulsation procedure with 5-day course of daily oral azithromycin for meibomian gland dysfunction.

Kodavoor S, Jayashri M, Patekar K, Ramamurthy S, Sachdev G Oman J Ophthalmol. 2024; 17(1):102-107.

PMID: 38524351 PMC: 10957040. DOI: 10.4103/ojo.ojo_114_22.


Quality of life improvement in dry eye patients after intense pulsed light therapy compared to punctal plugs.

Elbakary M, Shalaby O, Allam W, Alagorie A, Shafik H Oman J Ophthalmol. 2024; 17(1):108-112.

PMID: 38524331 PMC: 10957059. DOI: 10.4103/ojo.ojo_85_23.


References
1.
Torkildsen G, Cockrum P, Meier E, Hammonds W, Silverstein B, Silverstein S . Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin. 2010; 27(1):171-8. DOI: 10.1185/03007995.2010.539603. View

2.
Sullivan B, Evans J, Cermak J, Krenzer K, Dana M, Sullivan D . Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. Arch Ophthalmol. 2002; 120(12):1689-99. DOI: 10.1001/archopht.120.12.1689. View

3.
Maskin S . Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea. 2010; 29(10):1145-52. DOI: 10.1097/ICO.0b013e3181d836f3. View

4.
Greiner J . Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. 2012; 41(6):524-30. DOI: 10.1111/ceo.12033. View

5.
Lane S, DuBiner H, Epstein R, Ernest P, Greiner J, Hardten D . A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012; 31(4):396-404. DOI: 10.1097/ICO.0b013e318239aaea. View